Mirtazapina Ratiopharm (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Ratiopharm, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for buccal, oral, and sublingual use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapina Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts within the central nervous system to modify neurotransmitter activity in depressive disorders. - Major depressive disorder: reduces depressive symptoms and improves mood in adults. - Depression with insomnia: promotes sleep continuity and reduces nighttime awakenings. - Depression with anxiety: alleviates anxiety symptoms that coexist with depressive episodes.

Mirtazapine may cause a range of adverse reactions, some of which are frequent and others that are uncommon but serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Dizziness

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Hepatotoxicity - Seizures - Hyponatremia or syndrome of inappropriate antidiuretic hormone secretion

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events. - Hepatic function: assess liver enzymes in patients with known liver disease. - Weight monitoring: track body weight regularly due to risk of gain. - Suicidal ideation: observe for emergence or worsening of suicidal thoughts, especially early in treatment. - Elderly patients: use caution because of increased fall risk from sedation. - Discontinuation: avoid abrupt cessation to reduce withdrawal phenomena. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Central nervous system depressants (e.g., alcohol, benzodiazepines): additive sedation. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increased mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: possible additive blood pressure lowering. - Anticholinergic drugs: may exacerbate dry mouth and constipation.